Stock Ratings / Health Care / RIGL / dividends

KURA (29) AKTS (56) ORIC (39) CYRX (38) ⌘ Pro Terminal →

Rigel Pharmaceuticals Inc. (RIGL) Dividend Safety Gauge & 10-Year DRIP Compounder

$51.45 +1.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $51.70

Rigel Pharmaceuticals Inc. (RIGL) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (93% profit margin, 28% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate) →

ROARABLE B • BUY Cap $961.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $51.70 (+0.49%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 25.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RIGL)Realized 20D OHLCV Swing Band: ±7.8%

Deterministic 5-Pillar Attribution (74/100 Composite)

🔍 WHY RIGL SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+18/20 pts (24% of score)

FRED Regime × Technicals: 96% of 52W Range • RSI-14 at 64.4 (BULLISH MOMENTUM)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$49.08-6.3% Next Q

Q2 (-2Q)

Grade B-$45.97+4.7% Next Q

Q3 (-1Q)

Grade B$48.13+6.9% Next Q

Current

Grade B$51.45+7.3% Hist 90D α

Trajectory: B- (66) → B (74)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RIGL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, RIGL faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 90.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($47.69) or 200D SMA ($37.15) invalidates the momentum regime and cuts Target Base ($55.15) toward Bear Floor ($42.19).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RIGL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RIGL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 74%NO 26%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,269

Est. Year-10 Shareholder Yield: $815/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.5K

Yr 2

$15.7K

Yr 3

$18.3K

Yr 4

$21.3K

Yr 5

$24.7K

Yr 6

$28.8K

Yr 7

$33.5K

Yr 8

$38.9K

Yr 9

$45.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in RIGL & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on RIGL and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RIGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +78.03%▲ ASCENDING CHANNEL

2026-10-30O $51.80H $52.61L $50.67C $51.45VOL 174.2K

RES: $55.96SUP: $47.94SMA50: $47.69SMA200: $37.15

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RIGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RIGL Butterfly Map → + Track RIGL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-3.0%/yr Implied 5Y Growth

vs. +64.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RIGL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RIGL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RIGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RIGL)

Health Care Rank #56 of 1016 ⚔️ KURA vs RIGL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RIGL vs. KURA, AKTS, ORIC, CYRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rigel Pharmaceuticals Inc. (RIGL) ranks #56 by composite RQD confidence (74/100, grade B) and #363 by equity capitalization ($961.1M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while RIGL leads on capital efficiency and profitability with 28.2% ROIC and 93.3% gross margin. RIGL currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RIGL ACTIVE Rigel Pharmaceuticals Inc.	B	74/100	—	93.3%	28.2%	+1.40%	$961.1M	Benchmark Subject
KURA Kura Oncology Inc.	E	29/100	—	—	-35.0%	-1.49%	$939.4M	/kura-vs-rigl →
AKTS Aktis Oncology Inc.	D+	56/100	—	—	—	+0.18%	$937.2M	/akts-vs-rigl →
ORIC Oric Pharmaceuticals Inc.	D-	39/100	—	—	-33.4%	-3.33%	$931.8M	/oric-vs-rigl →
CYRX CryoPort Inc.	D-	38/100	11.8x	47.1%	-11.5%	-1.88%	$926.4M	/cyrx-vs-rigl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001034842

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rigel Pharmaceuticals Inc. (RIGL) reported GAAP revenue of $294.3M (+64.1% vs. FY2024 revenue of $179.3M , and +151.8% cumulative change since FY2023) , GAAP net income of $367.0M, operating cash flow of $75.7M, and free cash flow of $75.7M (+140.4% YoY). On the balance sheet, RIGL closed FY2025 with $513.6M in total assets against $0 in total debt (Altman Z-Score: 3.64, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$294.3M	$367.0M	$75.7M	$75.7M	$513.6M	—
FY2024 (FY)	2024-12-31	$179.3M	$17.5M	$31.5M	$31.5M	$164.0M	—
FY2023 (FY)	2023-12-31	$116.9M	-$25.1M	-$5.7M	-$5.7M	—	—

3. RIGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RIGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $51.45 (+1.40% 1D, market cap $961.1M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, RIGL ranks #56 in composite RQD confidence.

How does RIGL compare to KURA and AKTS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RIGL carries a Roarable B (74/100 RQD), trailing P/E of N/A, gross margin of 93.3%, and ROIC of 28.2%. By comparison, KURA (Kura Oncology Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $939.4M) and AKTS (Aktis Oncology Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $937.2M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while RIGL leads on capital efficiency (28.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RIGL?

Per RIGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001034842), Rigel Pharmaceuticals Inc. generated $294.3M in revenue (+64.1% YoY), $367.0M in net income, and $75.7M in free cash flow against $513.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RIGL trading relative to its 50-day, 200-day, and 52-week technical levels?

RIGL last traded at $51.45 (+1.40% on volume of 159,584 shares), positioning the stock +7.88% above its 50-day simple moving average ($47.69) and +38.49% above its 200-day simple moving average ($37.15). Across its 52-week range of $24.95 to $52.61, RIGL sits at the 95.8% percentile with a 14-day RSI of 64.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.8% ($47.44 to $55.46).

RIGL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does RIGL pay a dividend and is it safe?

Rigel Pharmaceuticals Inc. (RIGL) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: RIGL RQD Cockpit RIGL 12M Forecast RIGL Earnings & Move RIGL Dividends & DRIP RIGL Insiders & 13F RIGL Whale Options RIGL Profit Sankey RIGL News & Why